Skip to Main Content

Paper Details

Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues.
Circulation
18
2019
Glucose, HF, Heart Failure, Heart failure, Patients, Sodium, Sodium Glucose Cotransporter 2, Type 2 Diabetes Mellitus, cardiovascular death, glucose, myocardial infarction, nonfatal stroke, sodium, sodium glucose cotransporter 2, type 2 diabetes mellitus
Author NameAffiliation
Milton PackerBaylor University Medical Center
Kevin J AnstromDuke Clinical Research Institute
Gregg C FonarowAhmanson-university of california los angeles Cardiomyopathy Center, University of California Los Angeles (G.C.F.).
Gregg C FonarowAhmanson-university of california los angeles Cardiomyopathy Center, University of California Los Angeles (G.C.F.).
Adrian F HernandezDuke Clinical Research Institute
Adrian F HernandezDuke University School of Medicine
Mariell Jessup
Mariell Jessup
Mikhail KosiborodSaint Luke's Mid America Heart Institute, University of Missouri-Kansas City (M.K.).
Mikhail KosiborodThe George Institute for Global Health, University of New South Wales
JoAnn LindenfeldVanderbilt Heart and Vascular Institute
Marc S SabatineBrigham and Women's Hospital
Marc S SabatineBrigham and Women's Hospital
Marc S SabatineBrigham and Women's Hospital
Marc S SabatineBrigham and Women's Hospital
John R TeerlinkSan Francisco Veterans Affairs Medical Center
John R TeerlinkUniversity of California san francisco
Norman Stockbridge
  • 1 - 18

Datasets

Release 1.2